Clinical Trial Update: Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating a bispecific antibody-based salvage therapy followed by CAR-T cell therapy, with or without autologous stem cell transplant, i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Bispecific antibody-based salvage therapy
• CAR-T cell therapy

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Relapsed or Refractory Aggressive B-cell Lymphoma | Phase 2 | Status: RECRUITING